Stock List

Search by Ticker



Regeneron Pharmaceuticals (NASDAQ:REGN)
Stock Analysis

▼ -0.34%-2.06

Stock Analysis

The following stock analysis is based on 7.2 years of data (i.e. since Jun 10, 2013). All the stock history has been downloaded.

Stock Exchange

Regeneron Pharmaceuticals trades on the NasdaqGS exchange in USD dollars.


It is in the sector.

Current Status of Regeneron Pharmaceuticals

It is currently trading at $606.18 ($608.24 the previous day).


The next reporting date is in 84 days (2020 11 04).

CNN estimates profits for the upcoming quarter will be $7.29 per share ($2.1B). The current Canada / US exchange rate is 1.32784.

Over the past 12 months, $0 worth of shares have been purchased and $306853938 worth of shares have been sold by insiders.

Will This Trend Continue?

The year over year average increase is 0.5% per year assuming steady exponential growth. The actual 5 year average is -2.36. Details on the individual increase in one year intervals is provided below.

Past PerformanceAverage PricePercent Change
1 year384.964244897965.7+ Above Average
2 year364.31341365462-0.8+ Above Average
3 year367.41539748954-10.6- Below Average
4 year411.03330612245-8.5- Below Average
5 year449.039923954372.4+ Above Average
Regeneron Pharmaceuticals is projected by analysts to get to $675.00 within the next 12 months (11.4%), but preticted targets range from as high as $800.00 (32%) and as low as $550(-9.3%).


The worst drop it has had in recent years is -53.8%. It has a shape to the stock curve, which means

Stock shape test


With an average increase of 0.5% year over year, if Regeneron Pharmaceuticals is bought at the worst time, Stockmarketizer analysts estimate it will take 1291.2 months before the stock will recover to the original purchase price. The P/E value is 23.47.

Tradingview BuySell Widget

Yahoo News Feed

Is Regeneron Pharmaceuticals (REGN) Outperforming Other Medical Stocks This Year?

Tue, 11 Aug 2020 15:30:03 Is (REGN) Outperforming Other Medical Stocks This Year?... Read Full Article

Sanofi -- Moodyand's announces completion of a periodic review of ratings of Sanofi

Tue, 11 Aug 2020 14:39:10 Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Sanofi and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of ...... Read Full Article

Regeneron’s Covid-19 Treatment Could Be as Big a Deal as a Vaccine

Mon, 10 Aug 2020 18:11:00 Biotech Regeneron Pharmaceuticals has a cocktail of antibodies for treating Covid-19. Cannacord analyst John Newman says the treatment is “critical” because a vaccine can’t treat an active disease.... Read Full Article

Omeros Reports Coronavirus Treatment Success; Stock Soars

Mon, 10 Aug 2020 13:01:23 Small Omeros on Monday reported success with a test of its corononavirus treatment, saying it helped the recovery of six patients severely ill with Covid-19.... Read Full Article

Regeneron Prices $1.25B Public Offering; Analyst Cautious On Valuation

Mon, 10 Aug 2020 09:01:14 Regeneron Pharmaceuticals (REGN) has now announced the pricing of an underwritten offering of $1.250 billion aggregate principal amount of senior unsecured notes due 2030 and $750 million aggregate principal amount of senior unsecured notes due 2050.The 2030 notes will bear interest at 1.750% per annum ...... Read Full Article

Regeneron Announces Pricing of Public Offering of Senior Unsecured Notes

Fri, 07 Aug 2020 20:05:00 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the pricing of an underwritten offering of $1.250 billion aggregate principal amount of senior unsecured notes due 2030 (the and"2030 notesand") and $750 million aggregate principal amount of senior unsecured notes due 2050 (the and"2050 notesand" and, ...... Read Full Article

Regeneron Pharmaceuticals, Inc. -- Moodyand's assigns Baa3 issuer rating to Regeneron

Fri, 07 Aug 2020 18:14:10 NOTE: On August 07, 2020, the press release was corrected as follows: In the debt list, the description under “Ratings assigned” was changed to “Issuer rating, Baa3.” Revised release follows. New York, August 05, 2020 -- Moody's Investors Service ("Moody's") assigned a Baa3 issuer ...... Read Full Article

Regeneron Pharmaceuticals, Inc. -- Moodyand's rates Regeneronand's sr. notes Baa3; stable outlook

Fri, 07 Aug 2020 14:58:07 Moody's Investors Service ("Moody's") assigned a Baa3 rating to the new senior unsecured notes of Regeneron Pharmaceuticals, Inc. ("Regeneron"). "Regeneron's investment grade rating reflects growing global scale, strong scientific expertise, and an extremely conservative balance sheet, with very low financial ...... Read Full Article

Jim Cramer: No Shinola! Sellers Are Wrong on These 3 Stocks

Wed, 05 Aug 2020 23:01:00 People got a kick out of what I said at the top of "Mad Money" on Tuesday night, that the buyers and sellers are sometimes so stupid that they make moves that a bag of hammers would know better to ...... Read Full Article

Regeneron Earnings Easily Beat Views, But REGN Stock Slips

Wed, 05 Aug 2020 20:28:57 Regeneron topped second-quarter earnings and sales views. But the stock dipped on the news in morning trades Wednesday. The biotech giant is working on a number of coronavirus treatments.... Read Full Article

US STOCKS-Wall St gains on Disneyand's surprise profit, fiscal aid hopes

Wed, 05 Aug 2020 16:00:51 Wall Street's main indexes rose on Wednesday following upbeat services industry survey and Disney's surprise quarterly profit, with sentiment aided by signs that a coronavirus fiscal relief package was imminent. White House negotiators on Tuesday vowed to work "around the ...... Read Full Article

Regeneronand's (REGN) Q2 Earnings andand Sales Surpass Estimates

Wed, 05 Aug 2020 15:27:03 Regeneron (REGN) beats on Q2 earnings and sales on solid performance of Dupixent and oncology drug, Libtayo.... Read Full Article

Regeneron Stock Is Not Cheap - But It Could Be Undervalued

Wed, 05 Aug 2020 15:00:00 Ask yourself: Would you pay a higher multiple for the company that puts together a successful cocktail for Covid-19?... Read Full Article

US STOCKS-Wall St rises on Disneyand's surprise profit, services sector data

Wed, 05 Aug 2020 14:46:10 Walt Disney Co's shares jumped 8.9% to hit a more than five-month high as revenue declines for its parks and media networks were not as bad as feared. Drugstore operator and health insurer CVS Health Corp topped estimates for quarterly profit ...... Read Full Article

Regeneron Stock Climbs as Earnings Come in Strong

Wed, 05 Aug 2020 13:02:00 The company reported double-digit growth on both the top and bottom lines. Monday, it reported promising results from an animal trial of a treatment and preventative for Covid-19.... Read Full Article

Regeneron profit beats, expects early results from COVID-19 trials in September

Wed, 05 Aug 2020 12:36:31 Regeneron is among several drugmakers racing to develop a treatment for the novel coronavirus and earlier this week said its experimental COVID-19 antibody drug combination, REGN-COV2, prevented and treated the disease in rhesus macaques and hamsters. Continued lockdowns to curb ...... Read Full Article

US STOCKS-Wall St set to rise on Disneyand's surprise profit, upbeat healthcare results

Wed, 05 Aug 2020 12:32:55 Wall Street's main indexes were set to open higher on Wednesday as Disney's surprise quarterly profit and a slate of upbeat results from healthcare companies lifted sentiment ahead of service sector data. Walt Disney Co shares jumped 6.6% premarket and were ...... Read Full Article

Regeneron (REGN) Tops Q2 Earnings and Revenue Estimates

Wed, 05 Aug 2020 12:15:12 Regeneron (REGN) delivered earnings and revenue surprises of 14.93% and 9.05%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?... Read Full Article

Regeneron Pharmaceuticals: Q2 Earnings Insights

Wed, 05 Aug 2020 11:24:25 Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) rose 1.5% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share increased 18.54% year over year to $7.16, which beat the estimate of $5.98.Revenue of $1,952,000,000 up by 0.93% from the same period last ...... Read Full Article

Regeneronand's stock rallies toward a record after profit, revenue beat expectations

Wed, 05 Aug 2020 10:59:00 Shares of Regeneron Pharmaceuticals Inc. ran up 3.2% toward a record high in premarket trading Wednesday, after the biotechnology company reported second-quarter profit and revenue that beat Wall Street expectations, and said it expects clinical studies to remain generally on track ...... Read Full Article